|
CA3004716C
(en)
|
2008-04-29 |
2022-04-12 |
Ascendis Pharma Endocrinology Division A/S |
Pegylated recombinant human growth hormone compounds
|
|
SG181648A1
(en)
|
2009-12-15 |
2012-07-30 |
Ascendis Pharma As |
Dry growth hormone composition transiently linked to a polymer carrier
|
|
DK2571510T3
(en)
|
2010-05-21 |
2018-11-19 |
Xl Protein Gmbh |
BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
|
|
US20140323402A1
(en)
*
|
2011-08-12 |
2014-10-30 |
Ascendis Phama A/S |
Protein Carrier-Linked Prodrugs
|
|
CN107496932A
(zh)
*
|
2012-02-27 |
2017-12-22 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN104411324A
(zh)
|
2012-04-04 |
2015-03-11 |
哈洛齐梅公司 |
使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
|
|
WO2014114660A1
(en)
|
2013-01-22 |
2014-07-31 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
|
|
JP6259207B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
エラスチン産生促進剤
|
|
JP6259209B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
コラーゲン産生促進剤
|
|
JP6259208B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
ヒアルロン酸産生促進剤
|
|
US20160296600A1
(en)
|
2013-11-11 |
2016-10-13 |
Ascendis Pharma Relaxin Division A/S |
Relaxin Prodrugs
|
|
US9618507B2
(en)
|
2014-02-24 |
2017-04-11 |
Betanien Hospital |
Methods of treating rheumatoid arthritis
|
|
EP3113792B1
(en)
|
2014-03-05 |
2018-12-05 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
|
PL228341B1
(pl)
*
|
2014-04-21 |
2018-03-30 |
Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia |
Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
|
|
EP3185881B1
(en)
|
2014-08-26 |
2022-03-09 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
KR20250059541A
(ko)
|
2014-11-18 |
2025-05-02 |
아센디스 파마 엔도크리놀로지 디비전 에이/에스 |
신규한 중합체성 hGH 프로드러그
|
|
PT3220892T
(pt)
|
2014-11-21 |
2021-11-05 |
Ascendis Pharma Endocrinology Div A/S |
Formas de dosagem de hormona do crescimento de longa ação
|
|
WO2016193380A1
(en)
|
2015-06-02 |
2016-12-08 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
|
US10789711B2
(en)
*
|
2015-09-09 |
2020-09-29 |
Technische Universiteit Eindhoven |
Imaging of dispersion and velocity of contrast agents
|
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
|
US11186615B2
(en)
*
|
2015-10-08 |
2021-11-30 |
The Governors Of The University Of Alberta |
Hepatitis C virus E1/E2 heterodimers and methods of producing same
|
|
KR102654180B1
(ko)
|
2015-12-22 |
2024-04-04 |
엑스엘-프로테인 게엠베하 |
프롤린 및 알라닌 잔기가 풍부한 반복적인 아미노산 서열을 암호화하고 낮은 반복적인 뉴클레오티드 서열을 갖는 핵산
|
|
PL3393496T3
(pl)
|
2015-12-23 |
2024-04-22 |
The Johns Hopkins University |
Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
|
|
EP3400022A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low initial npr-b activity
|
|
WO2017118693A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
CA3008017C
(en)
|
2016-01-08 |
2024-01-02 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
MX2018008050A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
|
|
BR112018011008A2
(en)
|
2016-01-08 |
2018-12-04 |
Ascendis Pharma Growth Disorders A/S |
low npr-c binding controlled release cnp agonists
|
|
LT3400019T
(lt)
|
2016-01-08 |
2022-12-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
|
|
EP3405480B1
(en)
|
2016-01-20 |
2022-08-03 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
|
BR112018017091A2
(pt)
|
2016-03-01 |
2019-01-02 |
Ascendis Pharma Bone Diseases As |
profármacos de pth
|
|
ES2893838T3
(es)
|
2016-03-02 |
2022-02-10 |
Merz Pharma Gmbh & Co Kgaa |
Composición que comprende toxina botulínica
|
|
WO2017173346A1
(en)
*
|
2016-04-01 |
2017-10-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Par3 mimetic peptides and uses thereof
|
|
JP2019526526A
(ja)
*
|
2016-05-04 |
2019-09-19 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
|
|
EP3484523A1
(en)
|
2016-07-13 |
2019-05-22 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
NZ751745A
(en)
|
2016-09-29 |
2023-05-26 |
Ascendis Pharma Bone Diseases As |
Pth compounds with low peak-to-trough ratios
|
|
ES3012647T3
(en)
|
2016-09-29 |
2025-04-09 |
Ascendis Pharma Bone Diseases As |
Controlled-release pth compounds
|
|
CN109789189B
(zh)
|
2016-09-29 |
2024-01-23 |
阿森迪斯药物骨疾病股份有限公司 |
控释pth化合物的剂量方案
|
|
HUE062117T2
(hu)
|
2016-09-29 |
2023-09-28 |
Ascendis Pharma Growth Disorders As |
Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
WO2018093274A1
(en)
*
|
2016-11-16 |
2018-05-24 |
Auckland Uniservices Limited |
Methods for protein ligation and uses thereof
|
|
WO2018185131A2
(en)
|
2017-04-05 |
2018-10-11 |
Novo Nordisk A/S |
Oligomer extended insulin-fc conjugates
|
|
EP3642222A1
(en)
|
2017-06-20 |
2020-04-29 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum toxin with increased duration of effect
|
|
US10174302B1
(en)
*
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
|
WO2018234455A1
(en)
|
2017-06-21 |
2018-12-27 |
Xl-Protein Gmbh |
Conjugates of protein drugs and p/a peptides
|
|
EP3418383A1
(en)
|
2017-06-21 |
2018-12-26 |
XL-protein GmbH |
Modified l-asparaginase
|
|
FI3642340T3
(fi)
*
|
2017-06-21 |
2024-06-18 |
Jazz Pharmaceuticals Ireland Ltd |
Muunneltu l-asparaginaasi
|
|
EP3649143B1
(en)
|
2017-07-06 |
2022-08-31 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
|
EP3483619A1
(en)
*
|
2017-11-13 |
2019-05-15 |
Technische Universität München |
Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
|
|
EP3713595A1
(en)
*
|
2017-11-22 |
2020-09-30 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum toxin with increased duration of effect
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
|
WO2019185706A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
|
MA52662A
(fr)
|
2018-03-28 |
2021-02-17 |
Ascendis Pharma Oncology Div A/S |
Conjugués d'il-2
|
|
TWI724392B
(zh)
*
|
2018-04-06 |
2021-04-11 |
美商美國禮來大藥廠 |
生長分化因子15促效劑化合物及其使用方法
|
|
HRP20250963T1
(hr)
|
2018-05-18 |
2025-10-10 |
Ascendis Pharma Bone Diseases A/S |
Početna doza pth konjugata
|
|
IL280880B2
(en)
|
2018-08-27 |
2025-04-01 |
Regeneron Pharma |
Using Raman Spectroscopy in Downstream Purification
|
|
KR20250154552A
(ko)
|
2018-09-27 |
2025-10-28 |
실리오 디벨럽먼트, 인크. |
마스킹된 사이토카인 폴리펩타이드
|
|
CN111153965A
(zh)
*
|
2018-11-07 |
2020-05-15 |
浙江道尔生物科技有限公司 |
用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
|
|
JP2022513626A
(ja)
|
2018-11-26 |
2022-02-09 |
ノバルティス アーゲー |
Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
|
|
EP3908832B1
(en)
*
|
2019-01-10 |
2025-12-03 |
Roswell Biotechnologies Inc. |
Conductive synthetic peptides for molecular electronics
|
|
KR102891411B1
(ko)
|
2019-02-11 |
2025-11-25 |
아센디스 파마 본 디지즈 에이/에스 |
Pth 접합체의 액체 약학 제제
|
|
WO2020165081A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
|
JP7524206B2
(ja)
|
2019-03-04 |
2024-07-29 |
アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス |
１日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
|
|
EP3714909A1
(en)
*
|
2019-03-28 |
2020-09-30 |
Industrie Biomediche Insubri S.A. |
Improved bone implant matrix comprising proline-rich peptide and method of preparing the same
|
|
US10784093B1
(en)
*
|
2019-04-04 |
2020-09-22 |
Thermo Finnigan Llc |
Chunking algorithm for processing long scan data from a sequence of mass spectrometry ion images
|
|
AU2020296297B2
(en)
|
2019-06-21 |
2025-06-12 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
|
AU2020296295B2
(en)
|
2019-06-21 |
2025-05-29 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
|
CN114026080A
(zh)
|
2019-06-21 |
2022-02-08 |
阿森迪斯药物股份有限公司 |
含有提供π-电子对的杂芳族氮的化合物的缀合物
|
|
CN115551530A
(zh)
|
2019-08-27 |
2022-12-30 |
通尼克斯制药有限公司 |
经修饰的tff2多肽
|
|
CA3156066A1
(en)
|
2019-10-25 |
2021-04-29 |
Mi Rim Choi |
Recombinant l-asparaginase
|
|
AU2020398327A1
(en)
|
2019-12-03 |
2022-07-14 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
WO2021113434A1
(en)
*
|
2019-12-03 |
2021-06-10 |
Rodan & Fields, Llc |
Peptides and compositions for inhibiting hair growth
|
|
EP4071178A4
(en)
*
|
2019-12-06 |
2024-10-09 |
Ajinomoto Co., Inc. |
METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER
|
|
AU2020419444A1
(en)
|
2020-01-03 |
2022-06-09 |
Ascendis Pharma A/S |
Conjugates undergoing intramolecular rearrangements
|
|
US20230042670A1
(en)
|
2020-01-13 |
2023-02-09 |
Ascendis Pharma Bone Diseases A/S |
Hypoparathyroidism Treatment
|
|
CN113527485B
(zh)
*
|
2020-04-17 |
2024-11-15 |
湖南麦济生物技术股份有限公司 |
抗人白细胞介素-4受体α抗体及其制备方法和应用
|
|
GB202007106D0
(en)
*
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
EP4192508A1
(en)
|
2020-08-05 |
2023-06-14 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
|
|
EP4217004A1
(en)
|
2020-09-28 |
2023-08-02 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
CA3200238A1
(en)
|
2020-12-22 |
2022-06-30 |
Jonas SCHILZ |
Antibodies specific for structurally disordered sequences
|
|
CN112843222B
(zh)
*
|
2021-01-21 |
2023-01-31 |
暨南大学 |
Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
|
|
BR112023018802A2
(pt)
|
2021-04-01 |
2023-10-31 |
Ascendis Pharma As |
Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
|
|
WO2023046732A1
(en)
|
2021-09-22 |
2023-03-30 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
CN119789847A
(zh)
|
2022-05-23 |
2025-04-08 |
阿森迪斯药物生长障碍股份有限公司 |
Cnp化合物的液体药物制剂
|
|
KR20250019100A
(ko)
|
2022-06-02 |
2025-02-07 |
아지노모토 가부시키가이샤 |
친화성 물질, 화합물, 항체 및 그것들의 염
|
|
CN115927347A
(zh)
*
|
2022-10-14 |
2023-04-07 |
杭州佰辰医学检验所有限公司 |
特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒
|
|
WO2024094673A1
(en)
|
2022-11-02 |
2024-05-10 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment regimen comprising two pth compounds
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
GB202218084D0
(en)
|
2022-12-01 |
2023-01-18 |
Volution Immuno Pharmaceuticals Sa |
Fusion proteins
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
WO2025051711A1
(en)
|
2023-09-04 |
2025-03-13 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025088193A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for efficient recombinant production of polypeptides
|
|
WO2025088192A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for the coupling of di(alkyl)amines to polypeptides
|
|
WO2025233381A1
(en)
|
2024-05-07 |
2025-11-13 |
Technische Universität München, in Vertretung des Freistaates Bayern |
Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
|